Cost-effectiveness of implantable cardioverter-defibrillators

European Heart Journal

Volumn 22, Issue 12, 2001, Pages 990-996

  Boriani, Giuseppe ^a   Biffi, M ^a   Martignani, C ^a   Gallina, M ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiarrhythmic drugs; Cardioverter defibrillator; Cost effectiveness; Sudden death; Ventricular fibrillation; Ventricular tachycardia

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MEVINOLIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; HEART ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUDDEN DEATH;

ADULT; AGED; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TACHYCARDIA, VENTRICULAR;

EID: 0034908360     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2371     Document Type: Review

References (40)

1. Treatment of sudden cardiac death
2. Frequency of sudden cardiac death and profiles at risk
3. What can we expect from prophylactic implantable cardioverter defibrillators?
4. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
5. A randomized study of the prevention of sudden death in patients with coronary artery disease
6. The relationship among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction
7. Prevalence and prognostic significance of ventricular arrrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results
8. Identifying patients at risk of sudden death after myocardial infarction
9. Prediction of late arrhythmic events after acute myocardial infarction fremo combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricuar tachycardia
10. Risk stratification after myocardial infarction: What is the clinical usefulness of programmed ventricular stimulation?
11. Mortality benefits and the implantable cardioverter defibrillator
12. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond
13. Interpretation of outcomes of antiarrhythmic clinical trials
14. Unsustained ventricular tachycardia. To treat or not to treat?
15. Cost and health implications of cholesterol lowering
16. Cost-effectiveness analysis in heart disease. Part II. Preventive therapies
17. Cost-effectiveness analysis in heart disease. Part III. Ischemia, congestive heart failure and arrhythmias
18. Cost-effective strategies in cardiology
19. An analysis of the cost effectiveness of the implantable defibrillator
20. Cost-effectiveness of the implantable cardioverter defibrillator: Effect of improved battery life and comparison with amiodarone therapy
21. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator
22. Cost-effectiveness of implantable cardioverter defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in post infarct sudden death survivors
23. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death
24. Hospitalization charges in the antiarrythmics versus implantable defibrillators (AVID) trial: The AVID economic analysis study (Abstr)
25. The cost-effectiveness of implantable cardiac defibrillators: Results from MADIT. Multicentre Automatic Defibrillator Trial
26. Cost savings with nonthoracotomy implantable cardioverter-defibrillators
27. Implanted cardioverter defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias
28. Continuing evolution of implantable cardioverter-defibrillators: Smaller size, longer life, improved cost-effectiveness
29. Clinical experience with downsized lower energy output implantable cardioverter-defibrillators
30. Can implantable cardioverter-defibrillator therapy reduce healthcare costs?
31. The implantable cardioverter defibrillator: Economic issues
32. Economic outcomes of implantable cardioverter defibrillators
33. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
34. Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction: A model
35. Care of patients with a low probability of acute myocardial infarction: Cost-effectiveness of alternatives to coronary-care-unit admission
36. Impact of the multicenter Automatic Defibrillator implantation trail on implantable cardioverter defibrillator indication trends
37. Pacemakers and ICD's in Europe: Results of the registry of the European Working Group on Cardiac pacing
38. The registry of the European Working Group on Cardiac Pacing
39. The registry of the European Working Group on Cardiac Pacing